Madrid, March 15 (EUROPA PRESS) –
A team from the University of Madrid Autonomous University (UAM), in collaboration with a researcher at the Karolinska Institute (Sweden), found that gene overload could be the key to developing new therapies for diabetes.
In particular, through deep gene analysis, experts have identified mutations in the gene encoding the TXNIP protein, a mutation that has been studied in relation to the thioredoxin system, one of the major cell protection systems. Oxidative stress essential for the synthesis and maintenance of new dielectric materials.
This mutation has never been confirmed in humans, so TXNIP has completely disappeared. In fact, previous research on the function of this protein in animal models has suggested that it could be a potentially interesting target for the treatment of diabetes. This is because excessive intake of TXNIP was associated with the regulation of diabetes levels in the treatment of diabetes. Blood ", which was published in the journal Expert Diabetes.
Thus, the results show for the first time the importance of TXNIP in human body metabolism regulation. "The results obtained from patient cells illustrate many of the symptoms observed in patients," the authors did a detailed study that confirmed that they could survive without TXNIP.
Similarly, the results show that partial inhibition of glycoprotein can play a role in regulating glucose metabolism in diabetic patients as long as blood lactate levels are properly controlled.
However, the researchers emphasized the importance of "caution" in the results because there is still much research to understand the precise role of TXNIP in human metabolism. So they recognized that research was needed. Offer antidiabetic cures for TXNIP.